Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ASMB

ASMB - Assembly Biosciences Inc Stock Price, Fair Value and News

13.32USD+0.53 (+4.14%)Market Closed
Watchlist

Market Summary

USD13.32+0.53
Market Closed
4.14%

ASMB Stock Price

View Fullscreen

ASMB RSI Chart

ASMB Valuation

Market Cap

72.9M

Price/Earnings (Trailing)

-1

Price/Sales (Trailing)

10.02

EV/EBITDA

-0.39

Price/Free Cashflow

-0.89

ASMB Price/Sales (Trailing)

ASMB Profitability

EBT Margin

-1488.52%

Return on Equity

-174.19%

Return on Assets

-140.74%

Free Cashflow Yield

-112.16%

ASMB Fundamentals

ASMB Revenue

Revenue (TTM)

6.3M

Rev. Growth (Yr)

145.31%

Rev. Growth (Qtr)

17.38%

ASMB Earnings

Earnings (TTM)

-72.7M

Earnings Growth (Yr)

37.7%

Earnings Growth (Qtr)

14.65%

Breaking Down ASMB Revenue

Last 7 days

-5.6%

Last 30 days

17.7%

Last 90 days

32.4%

Trailing 12 Months

-36.4%

How does ASMB drawdown profile look like?

ASMB Financial Health

Current Ratio

6.96

ASMB Investor Care

Shares Dilution (1Y)

34.71%

Diluted EPS (TTM)

-16.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
202160.9M42.7M24.5M6.3M
202016.2M52.5M82.8M79.1M
201915.1M15.0M14.9M16.0M
201811.9M12.8M14.4M14.8M
20173.0M6.0M7.5M9.0M
20161.7M1.9M1.8M1.5M
2015185.7K360.0K827.5K1.2M
2014192.7K184.3K176.0K167.7K
2013000201.0K

Tracking the Latest Insider Buys and Sells of Assembly Biosciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 18, 2024
schornstein alexander
bought
276,069
0.8
345,086
-
Jan 17, 2024
schornstein alexander
bought
235,195
0.784
299,994
-
Nov 21, 2023
schornstein alexander
bought
66,700
0.667
100,000
-
Nov 20, 2023
schornstein alexander
bought
215,400
0.718
300,000
-
Nov 17, 2023
white nicole s
sold
-328
0.689
-477
chief manufacturing officer
Oct 03, 2023
okazaki jason a
sold
-1,879
0.7953
-2,363
ceo and president
Oct 03, 2023
white nicole s
sold
-1,503
0.7953
-1,891
chief manufacturing officer
Oct 03, 2023
delaney william e iv
sold
-1,503
0.7953
-1,891
chief scientific officer
Oct 02, 2023
white nicole s
acquired
-
-
10,000
chief manufacturing officer
Oct 02, 2023
delaney william e iv
acquired
-
-
10,000
chief scientific officer

1–10 of 50

Which funds bought or sold ASMB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
36,821
36,821
-%
Feb 15, 2024
BARCLAYS PLC
unchanged
-
-3,000
29,000
-%
Feb 15, 2024
Baker Avenue Asset Management, LP
sold off
-100
-885
-
-%
Feb 14, 2024
CITADEL ADVISORS LLC
reduced
-9.85
-20,187
102,442
-%
Feb 14, 2024
TWO SIGMA ADVISERS, LP
added
155
15,722
27,227
-%
Feb 14, 2024
Royal Bank of Canada
new
-
-
-
-%
Feb 14, 2024
VANGUARD GROUP INC
added
4.42
-64,111
1,918,290
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
-11,293
142,697
-%

1–10 of 46

Are Funds Buying or Selling ASMB?

Are funds buying ASMB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ASMB
No. of Funds

Unveiling Assembly Biosciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Nov 22, 2023
schornstein alexander
11.51%
7,564,292
SC 13D/A
Nov 03, 2023
schornstein alexander
10.9%
7,164,292
SC 13D/A
Oct 31, 2023
schornstein alexander
-
0
SC 13D
Oct 25, 2023
gilead sciences, inc.
19.9%
13,073,668
SC 13D
Feb 14, 2023
deep track capital, lp
3.76%
1,833,437
SC 13G/A
Feb 15, 2022
armistice capital, llc
4.2%
2e+06
SC 13G/A
Feb 14, 2022
consonance capital management lp
-
0
SC 13G/A
Feb 14, 2022
deep track capital, lp
6.27%
3e+06
SC 13G/A
Feb 09, 2022
vanguard group inc
4.61%
2,205,053
SC 13G/A
Oct 12, 2021
deep track capital, lp
5.32%
2,393,876
SC 13G

Recent SEC filings of Assembly Biosciences Inc

View All Filings
Date Filed Form Type Document
Feb 13, 2024
8-K
Current Report
Feb 02, 2024
8-K
Current Report
Jan 19, 2024
4
Insider Trading
Jan 17, 2024
8-K
Current Report
Dec 21, 2023
DEFA14A
DEFA14A
Dec 21, 2023
DEF 14A
DEF 14A
Dec 11, 2023
PRE 14A
PRE 14A
Dec 11, 2023
3
Insider Trading
Dec 07, 2023
8-K
Current Report
Nov 22, 2023
SC 13D/A
13D - Major Acquisition

Peers (Alternatives to Assembly Biosciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.3B
6.8B
-16.59% -47.80%
-7.7
5.3
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.2B
1.8B
-23.99% -31.71%
-43.66
10.51
76.23% 61.08%
16.4B
2.4B
-4.89% -18.90%
98.05
6.79
15.42% 18.43%
13.3B
3.7B
-7.62% -26.87%
22.19
3.59
8.87% 75.42%
MID-CAP
7.7B
396.6M
-2.06% 34.31%
-14.57
19.42
425.83% 18.94%
6.3B
-
-3.85% 226.12%
-10.06
60.35
54.84% -25.61%
4.5B
240.7M
-19.08% -10.99%
-15.05
18.56
-1.03% -92.09%
4.0B
726.4M
-12.60% 32.37%
-64.55
5.45
40.45% 71.62%
3.9B
270.6M
8.92% 47.81%
-16.3
14.41
440.80% -27.84%
SMALL-CAP
2.0B
398.2M
-3.38% -9.50%
28.08
5.03
85.90% -14.05%
752.9M
983.7M
-9.17% -57.89%
-1.38
0.77
-50.36% 17.16%
217.0M
4.9M
-14.18% -58.18%
-1.32
44.39
-57.57% 50.48%
154.8M
881.7K
289.54% 381.25%
-3.26
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Assembly Biosciences Inc News

Latest updates
InvestorsObserver14 Feb 202404:08 pm
InvestorsObserver06 Feb 202408:00 am

Assembly Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue17.4%628,000535,000442,000349,000256,000170,66785,333-6,254,0004,515,0002,776,0001,037,00034,611,00039,376,0004,081,0004,767,0004,231,0003,080,0003,885,0003,735,0004,286,000
Costs and Expenses---------------------26,861,411
Operating Expenses-14.0%15,048,00017,488,00019,559,00022,978,00023,401,00024,573,00023,162,00062,889,00025,129,00023,666,00027,258,00040,679,00038,630,00032,797,00031,775,00033,451,00030,224,00022,780,00032,221,00030,057,00026,861,000
  S&GA Expenses-14.9%4,224,0004,965,0005,012,0006,125,0005,271,0006,781,0005,957,0006,504,0006,655,0006,917,0008,704,0007,170,00011,689,0009,470,0008,729,00010,834,0008,488,0004,080,0009,517,0008,806,0007,752,000
  R&D Expenses-13.6%10,824,00012,523,00014,547,00016,853,00018,130,00017,792,00017,205,00014,747,00018,474,00016,749,00018,554,00033,509,00026,941,00023,327,00023,046,00022,616,50021,736,00018,700,00022,704,00021,251,00019,109,000
EBITDA Margin0.0%-14.79-14.79-14.79-14.79-21.07-21.07-21.07-21.08-2.51-1.44-1.01-0.78---------
Income Taxes-----------------741,000-15,000-11,000-7,0001,139,000-6,000
Earnings Before Taxes-------------39,418,000-3,349,0007,270,000-26,655,000-27,825,000-25,010,000-18,514,000-27,059,000-25,022,000-21,541,000
EBT Margin0%-14.89-14.89-14.89-14.89-21.17-21.17-21.17-21.17-2.54-1.46-1.02-0.79---------
Net Income14.7%-14,420,000-16,896,000-18,950,000-22,395,000-23,145,000-24,461,000-23,091,000-60,257,000-18,803,000-23,595,000-27,200,000-39,418,000-3,349,0007,270,000-26,655,000-27,084,000-24,995,000-18,503,000-27,052,000-26,161,000-21,535,000
Net Income Margin10.7%-11.62-13.01-14.22-14.89-20.94-20.24-20.11-20.76-4.46-2.19-1.03-0.79---------
Free Cashflow-2.6%-13,984,000-13,628,000-23,428,000-19,254,000-19,924,000-17,885,000-27,502,000-19,380,000-18,882,000-21,808,000-36,422,000-25,269,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-22.5%52.0067.0083.00102122143163191249262279283306295313340223242259268283
  Current Assets-22.5%50.0064.0080.0097.00115124131154188206222224246235257283165183201223240
    Cash Equivalents23.3%27.0022.0043.0052.0055.0043.0051.0046.0071.0060.0078.0059.0058.0097.0042.0047.0025.0034.0029.0041.00120
  Net PPE3.7%1.001.001.001.001.001.001.001.001.001.001.002.002.002.002.002.002.002.002.001.001.00
  Goodwill---------13.0013.0013.0013.0013.0013.0013.0013.0013.0013.0013.0013.0013.00
Liabilities-14.7%10.0012.0013.0019.0019.0019.0016.0022.0024.0030.0032.0043.0036.0028.0062.0067.0067.0067.0069.0057.0054.00
  Current Liabilities-19.2%7.009.0010.0016.0015.0015.0011.0016.0015.0014.0014.0024.0017.0017.0021.0024.0021.0020.0025.0018.0015.00
Shareholder's Equity-24.1%42.0055.0070.0083.00102124147169225232247241271267252273156175190211229
  Retained Earnings-1.9%-774-760-743-724-702-678-654-631-571-552-528-501-462-458-466-439-412-387-368-341-315
  Additional Paid-In Capital0.1%817816814808805804802801796784776742733726718713569562559553545
Shares Outstanding0.3%4.004.004.004.004.004.004.004.004.004.003.003.00---------
Float------101---168---757---333---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-1.6%-13,848-13,628-23,428-19,254-19,822-17,885-27,502-19,362-18,882-21,808-33,344-25,26910,646-23,116-25,218-20,528-18,595-21,005-23,939-16,727-16,684
  Share Based Compensation-4.6%1,1351,1901,8352,0131,5561,5811,4431,9451,5921,986-2863,7476,0487,1344,9246,5095,4042,0686,5776,8076,006
Cashflow From Investing325.7%18,881-8,36510,00016,56231,4329,59733,049-8,48420,070-3,08718,01620,715-49,88776,54920,693-95,0227,81925,45011,435-62,159-73,600
Cashflow From Financing-100.0%-1344,492437-177-2,71310,0556,15934,1375,687843950119137,4151,385706140605155,844

ASMB Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses    
Research and development$ 10,824$ 18,130$ 37,894$ 53,127
General and administrative4,2245,27114,20118,009
Total operating expenses15,04823,40152,09571,136
Loss from operations(15,048)(23,401)(52,095)(71,136)
Other income    
Interest and other income, net6282561,829439
Total other income6282561,829439
Net loss(14,420)(23,145)(50,266)(70,697)
Other comprehensive loss    
Unrealized gain (loss) on marketable securities50(1)528(580)
Comprehensive loss$ (14,370)$ (23,146)$ (49,738)$ (71,277)
Net loss per share, basic$ (0.27)$ (0.48)$ (0.97)$ (1.46)
Net loss per share, diluted$ (0.27)$ (0.48)$ (0.97)$ (1.46)
Weighted average common shares outstanding, basic52,565,33348,448,39951,951,12348,289,501
Weighted average common shares outstanding, diluted52,565,33348,448,39951,951,12348,289,501

ASMB Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 26,656$ 52,418
Marketable securities - short-term19,55439,192
Accounts receivable from collaboration0944
Prepaid expenses and other current assets3,4624,413
Total current assets49,67296,967
Property and equipment, net561743
Operating lease right-of-use (ROU) assets8443,195
Other assets552889
Total assets51,629101,794
Current liabilities  
Accounts payable7582,493
Accrued research and development expenses1,6193,122
Other accrued expenses3,8867,317
Operating lease liabilities - short-term8693,364
Total current liabilities7,13216,296
Deferred revenue2,7332,733
Operating lease liabilities - long-term50101
Total liabilities9,91519,130
Commitments and contingencies
Stockholders' equity  
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 52,614,194 and 48,894,973 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively5349
Additional paid-in capital816,722807,938
Accumulated other comprehensive loss(275)(803)
Accumulated deficit(774,786)(724,520)
Total stockholders' equity41,71482,664
Total liabilities and stockholders' equity$ 51,629$ 101,794
ASMB
Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEwww.assemblybio.com
 EMPLOYEES70

Assembly Biosciences Inc Frequently Asked Questions


What is the ticker symbol for Assembly Biosciences Inc? What does ASMB stand for in stocks?

ASMB is the stock ticker symbol of Assembly Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Assembly Biosciences Inc (ASMB)?

As of Fri Mar 01 2024, market cap of Assembly Biosciences Inc is 72.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ASMB stock?

You can check ASMB's fair value in chart for subscribers.

What is the fair value of ASMB stock?

You can check ASMB's fair value in chart for subscribers. The fair value of Assembly Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Assembly Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ASMB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Assembly Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether ASMB is over valued or under valued. Whether Assembly Biosciences Inc is cheap or expensive depends on the assumptions which impact Assembly Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASMB.

What is Assembly Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Mar 01 2024, ASMB's PE ratio (Price to Earnings) is -1 and Price to Sales (PS) ratio is 10.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASMB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Assembly Biosciences Inc's stock?

In the past 10 years, Assembly Biosciences Inc has provided -0.191 (multiply by 100 for percentage) rate of return.